Gottfried E. Konecny, MD

Articles

Dr. Konecny on the Survival Benefit Achieved With Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Dr. Konecny on the Indications for PARP Inhibitors in Recurrent Ovarian Cancer

May 29th 2019

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.

Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

September 19th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Konecny on Response to PARP Inhibitors in Ovarian Cancer

August 3rd 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian Cancer

July 17th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Dr. Konecny Discusses the Role of PARP Inhibitors in Ovarian Cancer

June 7th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Konecny on the Use of PARP Inhibitors in Patients With Ovarian Cancer

May 29th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.